title: The insulin-like growth factor pathway as a target for cancer therapy.
abstract: The insulin-like growth factor (IGF) system is emerging as a promising new target in cancer therapy. Experimental models and epidemiological studies have demonstrated that the IGF system plays a key role in malignant transformation and cancer progression. Different strategies are being pursued to target this pathway. Several monoclonal antibodies and tyrosine kinase inhibitors targeting the IGF-1 receptor are in clinical development. Early clinical trials indicate these drugs have acceptable safety profiles, and there is pharmacodynamic evidence that actual target inhibition is achievable in patients. Emerging efficacy data as single agent and in combination with chemotherapy is encouraging yet too early for firm conclusions. This manuscript reviews the role of the IGF system in human malignancy and its interactions with other signaling pathways, and summarizes the available data of IGF-1R inhibitors currently in clinical trials.
authors.affiliation: Department of Medical Oncology, Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS), Sevilla, Spain.
authors.forename: Iker
authors.initials: I
authors.lastname: López-Calderero
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Sánchez Chávez
authors.forename: Rocío
authors.initials: R
authors.lastname: García-Carbonero
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002986:Clinical Trials as Topic / Q000379:methods; D016503:Drug Delivery Systems; D006801:Humans; D008954:Models, Biological; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D017526:Receptor, IGF Type 1 / Q000037:antagonists & inhibitors / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects / Q000235:genetics / Q000502:physiology; D013002:Somatomedins / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism / Q000502:physiology*
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D013002:Somatomedins; D017526:Receptor, IGF Type 1
references.citation: Annu Rev Biochem. 1992;61:307-30
references.pmid: 1323236
references.citation: Lancet Oncol. 2010 Feb;11(2):129-35
references.pmid: 20036194
references.citation: Ann Intern Med. 1995 Mar 1;122(5):327-34
references.pmid: 7847643
references.citation: Oncogene. 2005 Jul 7;24(29):4736-40
references.pmid: 15870705
references.citation: Indian J Med Res. 2007 Apr;125(4):511-22
references.pmid: 17598937
references.citation: N Engl J Med. 2004 Oct 14;351(16):1619-26
references.pmid: 15483280
references.citation: Proc Natl Acad Sci U S A. 2001 Jun 19;98(13):7200-5
references.pmid: 11404460
references.citation: Clin Cancer Res. 2007 Feb 15;13(4):1198-207
references.pmid: 17317830
references.citation: Cancer Res. 2003 Aug 1;63(15):4384-8
references.pmid: 12907608
references.citation: Clin Transl Oncol. 2009 Sep;11(9):572-9
references.pmid: 19775996
references.citation: Cancer Res. 2006 Oct 15;66(20):10100-11
references.pmid: 17047074
references.citation: J Clin Oncol. 2009 Dec 1;27(34):5800-7
references.pmid: 19786654
references.citation: Cancer Res. 2005 Dec 1;65(23):11118-28
references.pmid: 16322262
references.citation: Endocr Rev. 2001 Dec;22(6):800-17
references.pmid: 11739334
references.citation: Cancer Res. 1972 Feb;32(2):226-32
references.pmid: 5058183
references.citation: J Clin Oncol. 2008 Jul 1;26(19):3196-203
references.pmid: 18474873
references.citation: Cancer Res. 2005 Mar 15;65(6):2085-8
references.pmid: 15781617
references.citation: J Biol Chem. 2001 Oct 26;276(43):40080-6
references.pmid: 11457860
references.citation: J Natl Cancer Inst. 1999 Apr 7;91(7):620-5
references.pmid: 10203281
references.citation: BJU Int. 2008 Feb;101(4):436-9
references.pmid: 18234062
references.citation: Nat Clin Pract Oncol. 2007 Oct;4(10):591-602
references.pmid: 17898809
references.citation: Nature. 2006 May 25;441(7092):424-30
references.pmid: 16724053
references.citation: Oncogene. 2000 Feb 17;19(7):889-98
references.pmid: 10702797
references.citation: Mod Pathol. 2006 Jun;19(6):788-96
references.pmid: 16575403
references.citation: Science. 1998 Jan 23;279(5350):563-6
references.pmid: 9438850
references.citation: Mol Cancer Res. 2003 Feb;1(4):312-22
references.pmid: 12612059
references.citation: Cancer Res. 2005 May 1;65(9):3781-7
references.pmid: 15867374
references.citation: Endocr Relat Cancer. 2005 Dec;12(4):1017-36
references.pmid: 16322340
references.citation: Eur J Cancer. 1993;29A(16):2256-64
references.pmid: 8110496
references.citation: Biochem Biophys Res Commun. 2006 Apr 14;342(3):851-8
references.pmid: 16499871
references.citation: Arch Physiol Biochem. 2008 Feb;114(1):23-37
references.pmid: 18465356
references.citation: Nat Rev Drug Discov. 2002 Oct;1(10):769-83
references.pmid: 12360255
references.citation: Cancer Res. 2008 Mar 1;68(5):1538-45
references.pmid: 18316619
references.citation: Endocrinology. 2004 Nov;145(11):4976-84
references.pmid: 15271882
references.citation: J Natl Cancer Inst. 2006 Jan 18;98(2):123-34
references.pmid: 16418515
references.citation: Clin Cancer Res. 2007 Oct 1;13(19):5834-40
references.pmid: 17908976
references.citation: J Clin Oncol. 2009 May 20;27(15):2516-22
references.pmid: 19380445
references.citation: J Pharmacol Exp Ther. 2006 Aug;318(2):666-75
references.pmid: 16682453
references.citation: Proc Natl Acad Sci U S A. 1993 Dec 1;90(23):11217-21
references.pmid: 8248231
references.citation: Cancer Res. 2003 Mar 15;63(6):1166-71
references.pmid: 12649170
references.citation: Acta Physiol Hung. 2005;92(2):97-107
references.pmid: 16268048
references.citation: Proc Natl Acad Sci U S A. 2006 May 2;103(18):6901-6
references.pmid: 16641105
references.citation: Biochem J. 2007 May 1;403(3):603-13
references.pmid: 17291192
references.citation: Nature. 1995 Oct 19;377(6550):646-9
references.pmid: 7566179
references.citation: Proc Natl Acad Sci U S A. 2007 Dec 26;104(52):20926-31
references.pmid: 18087038
references.citation: Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3455-60
references.pmid: 10737798
references.citation: J Biol Chem. 2008 Feb 1;283(5):2604-13
references.pmid: 18048361
references.citation: Curr Opin Pharmacol. 2008 Aug;8(4):384-92
references.pmid: 18674638
references.citation: Clin Cancer Res. 2015 Feb 15;21(4):701-11
references.pmid: 25212606
references.citation: J Clin Oncol. 2009 Jan 10;27(2):176-85
references.pmid: 19064975
references.citation: J Clin Invest. 1963 Nov;42:1816-34
references.pmid: 14083170
references.citation: Cancer Res. 1984 Dec;44(12 Pt 1):5486-90
references.pmid: 6093996
references.citation: Curr Pharm Des. 2007;13(7):671-86
references.pmid: 17346183
references.citation: J Exp Med. 1995 Aug 1;182(2):593-7
references.pmid: 7543144
references.citation: J Cell Biochem. 2006 Oct 1;99(2):392-401
references.pmid: 16639715
references.citation: Oncogene. 2005 Aug 18;24(35):5510-20
references.pmid: 15897888
references.citation: Proc Natl Acad Sci U S A. 1976 Dec;73(12):4536-40
references.pmid: 1070004
references.citation: Clin Cancer Res. 2011 Oct 1;17(19):6304-12
references.pmid: 21810918
references.citation: Cancer Chemother Pharmacol. 2010 Mar;65(4):765-73
references.pmid: 19649631
references.citation: N Engl J Med. 2003 Apr 24;348(17):1625-38
references.pmid: 12711737
references.citation: J Biol Chem. 2001 Mar 30;276(13):9817-24
references.pmid: 11139588
references.citation: Int J Cancer. 1996 Aug 22;69(4):335-9
references.pmid: 8797879
references.citation: J Natl Cancer Inst. 2001 Dec 19;93(24):1852-7
references.pmid: 11752009
references.citation: J Clin Oncol. 2006 May 1;24(13):1982-9
references.pmid: 16648498
references.citation: Mol Cell Biol. 2006 Mar;26(5):1754-69
references.pmid: 16478996